http://www.pharmexec.com/pharmexec/Strategy/Article/list/43776 The art and science of running a successful pharmaceutical company. 2013-05-20T02:34:01Z http://www.pharmexec.com/pharmexec/Strategy/Connected-CRM-in-Life-Sciences/ArticleStandard/Article/detail/813124?contextCategoryId=43776&ref=25 This paper focuses on how customer centricity can unlock significant financial gains for pharmaceutical companies. It briefly reviews the historical promotion model, the factors in the industry that are driving the change, and then goes into depth on what it means to be customer centric and how to implement a customer-centric model. 2013-05-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202013/813124null REMOTE http://www.pharmexec.com/pharmexec/Strategy/Early-Engagement-with-Medical-Laboratories/ArticleStandard/Article/detail/808526?contextCategoryId=43776&ref=25 Timely engagement is the key to expanding the use of companion diagnostics. 2013-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122013/808526null XML http://www.pharmexec.com/pharmexec/Strategy/Test-and-Learn-Making-Confident-Decisions-on-the-C/ArticleStandard/Article/detail/808521?contextCategoryId=43776&ref=25 Companies that adopt this new methodology will have a longstanding competitive advantage over those companies conducting business as usual. 2013-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122013/808521null XML http://www.pharmexec.com/pharmexec/Strategy/Embedding-Market-Access-in-Todays-Pharma-Business-/ArticleStandard/Article/detail/808529?contextCategoryId=43776&ref=25 A proactive approach to talent and organization planning is the hidden trump card in prevailing with payers. 2013-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122013/808529null XML http://www.pharmexec.com/pharmexec/Strategy/Building-Clinical-Trial-Awareness-for-Patients-Why/ArticleStandard/Article/detail/808517?contextCategoryId=43776&ref=25 Ken Getz of the Tufts University Center for the Study of Drug Development (CSDD) explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol. 2013-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122013/808517null XML http://www.pharmexec.com/pharmexec/Strategy/Rethinking-Product-Lifecycle-Management/ArticleStandard/Article/detail/805006?contextCategoryId=43776&ref=25 "Drug Life Optimization" can wrest more value through strategies that build a drug's brand franchise through its entire lifespan, according to Stan Bernard. 2013-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062013/805006/Stan-Bernard_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/The-Scoop-on-Drug-Shortages/ArticleStandard/Article/detail/803316?contextCategoryId=43776&ref=25 New research sheds fresh light on a trend with serious consequences for the public health—not only in the United States but for patients worldwide. 2013-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042013/803316/drug_shortage_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042013/803316null XML http://www.pharmexec.com/pharmexec/Strategy/The-Battles-on-for-HR-Success-in-China/ArticleStandard/Article/detail/796498?contextCategoryId=43776&ref=25 Chinese start-ups have realized that they need to recruit highly skilled and globally oriented general managers from foreign multinationals when they reach a critical size. 2012-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462012/796498/Shangai_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462012/796498null XML http://www.pharmexec.com/pharmexec/Strategy/Market-Access-Roadmap/ArticleStandard/Article/detail/796501?contextCategoryId=43776&ref=25 Unified payer research planning is of top import. 2012-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462012/796501null XML http://www.pharmexec.com/pharmexec/Strategy/InsideOutsourcing/ArticleStandard/Article/detail/791350?contextCategoryId=43776&ref=25 2012-10-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402012/791350null HTML http://www.pharmexec.com/pharmexec/Strategy/Your-Local-Competitor-A-Threat-in-Emerging-Markets/ArticleStandard/Article/detail/791513?contextCategoryId=43776&ref=25 Pharmaceutical companies looking to wrest market share in high growth markets of tomorrow must overcome challenges from a new crop of national champions. 2012-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402012/791513/world_emerging_176_flash.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Lundbeck-Bidding-for-the-Stars-and-Stripes/ArticleStandard/Article/detail/791506?contextCategoryId=43776&ref=25 Pharm Exec takes a look at how a mid tier player — Denmark's Lundbeck — is counting on the momentum of the big US market to vault it to global leadership position. 2012-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402012/791506/Lundbeck-Group_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402012/791506null XML http://www.pharmexec.com/pharmexec/Strategy/Pharm-Execs-11th-Annual-Industry-Audit/ArticleStandard/Article/detail/788397?contextCategoryId=43776&ref=25 Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled. 2012-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372012/788397/industry_audit_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/The-Big-Sell-Biologics-In-Emerging-Markets/ArticleStandard/Article/detail/788390?contextCategoryId=43776&ref=25 High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell. 2012-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372012/788390/world_emerging_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Appointments/ArticleStandard/Article/detail/786423?contextCategoryId=43776&ref=25 world to improve the real world. The group brings value to over 150,000 customers of all sizes, in all industries, in more than 80 countries. For more information, visit www.3ds.com. 2012-08-29T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/352012/786423null HTML http://www.pharmexec.com/pharmexec/Strategy/Sunny-Outlook-for-Biopharm-2020/ArticleStandard/Article/detail/784893?contextCategoryId=43776&ref=25 Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020—just watch out for the harsh light of complacency. 2012-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322012/784893/horizon_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322012/784893null XML http://www.pharmexec.com/pharmexec/Strategy/Creallaborations-Pharma-Starts-Thinking-Outside-th/ArticleStandard/Article/detail/784890?contextCategoryId=43776&ref=25 Creative non-pharmaceutical partnerships can offer innovators unique capabilities against the competition in a new era where challenges to market leadership are coming from every direction. 2012-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322012/784890null XML http://www.pharmexec.com/pharmexec/Strategy/Data-Exclusivity-Making-the-Case/ArticleStandard/Article/detail/784892?contextCategoryId=43776&ref=25 As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine. 2012-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322012/784892null XML http://www.pharmexec.com/pharmexec/Strategy/Planning-that-Thousand-Year-Future/ArticleStandard/Article/detail/784899?contextCategoryId=43776&ref=25 Planning for the long term is increasingly seen as an abstract absurdity. But a lasting business model is still possible—if you learn to adapt. 2012-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322012/784899/telescope-future_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Todays-Mission-Critical-Making-Sense-of-Spending-o/ArticleStandard/Article/detail/780620?contextCategoryId=43776&ref=25 Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded—and lengthy—race to registration. 2012-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272012/780620null XML http://www.pharmexec.com/pharmexec/Strategy/The-Learning-Curve/ArticleStandard/Article/detail/780622?contextCategoryId=43776&ref=25 In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises—change for pharma is here and its good. 2012-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272012/780622null XML http://www.pharmexec.com/pharmexec/R%26D/Raising-the-Stakes-in-CNS/ArticleStandard/Article/detail/777872?contextCategoryId=43776&ref=25 As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory. 2012-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242012/777872/Photo-JJona-176_flash.gif XML http://www.pharmexec.com/pharmexec/Strategy/ACOs-are-Here-to-Stay-Even-if-the-ACA-is-Not/ArticleStandard/Article/detail/777875?contextCategoryId=43776&ref=25 No matter how the Supreme Court rules on healthcare reform, the accountable care model will stick around. To play ball with ACOs, drug companies will need to throw a different pitch. 2012-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242012/777875null XML http://www.pharmexec.com/pharmexec/Deals/2012-Dealmakers-Outlook/ArticleStandard/Article/detail/777876?contextCategoryId=43776&ref=25 Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead. 2012-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242012/777876/dealmaker_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Value-Based-Pricing-Too-High-a-Price-for-UK-Pharma/ArticleStandard/Article/detail/773567?contextCategoryId=43776&ref=25 Will changes to the P&R system in the UK finally put some real metrics behind the elusive concept of value? 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773567/British_money_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773567null XML http://www.pharmexec.com/pharmexec/Strategy/Navigating-MampA-Complexities/ArticleStandard/Article/detail/767905?contextCategoryId=43776&ref=25 Too often in M&A or product-linked carve-outs, executives overlook the complexities of disentangling operations and the effort required for regulatory re-registration and labeling changes. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767905null XML http://www.pharmexec.com/pharmexec/Strategy/Novartis-LEADing-in-Emerging-Markets/ArticleStandard/Article/detail/764163?contextCategoryId=43776&ref=25 With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition. 2012-03-12T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764163/Jimenez_120_art_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/The-Life-Science-of-Digital-Connections/ArticleStandard/Article/detail/764165?contextCategoryId=43776&ref=25 Making real connections that resonate with audiences in a digital world is a fine art, especially in the heavily regulated world of Big Pharma 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764165null XML http://www.pharmexec.com/pharmexec/Strategy/Off-the-Hook-Pharm-Execs-Annual-Press-Audit/ArticleStandard/Article/detail/764160?contextCategoryId=43776&ref=25 Our annual press audit finds that the big news in 2011 for pharma was ... no news. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764160/pharma_&_press_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Prizing-the-Eye--Brent-Saunders-CEO-Bausch---Lomb/ArticleStandard/Article/detail/757967?contextCategoryId=43776&ref=25 Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company". 2012-02-01T05:00:00Z XML http://www.pharmexec.com/pharmexec/Strategy/Sales-Force-Survey-Still-Too-Much-Business-as-Usua/ArticleStandard/Article/detail/757953?contextCategoryId=43776&ref=25 In the global battle for market share, the ability to adapt and mobilize your human assets around a responsive commercial model is a key variable of success. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757953/sales-survey_flash_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Best-to-Market/ArticleStandard/Article/detail/757966?contextCategoryId=43776&ref=25 Pharm Exec's Brand of the Year: Abbott's Humira 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757966null XML http://www.pharmexec.com/pharmexec/Legal/Compliance-Getting-Those-Ducks-in-a-Row/ArticleStandard/Article/detail/755089?contextCategoryId=43776&ref=25 Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755089/Ducks-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755089null XML http://www.pharmexec.com/pharmexec/Commentary/Copay-Cards-and-Coupons-Letting-the-Facts-Get-in-t/ArticleStandard/Article/detail/755091?contextCategoryId=43776&ref=25 Mason Tenaglia offers empirical defense of coupons and copay offset programs. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755091/tenaglia_mason_1481_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755091null XML http://www.pharmexec.com/pharmexec/Technology/iPad-Apps-Are-You-Content-with-your-Content/ArticleStandard/Article/detail/755081?contextCategoryId=43776&ref=25 Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755081/ipad-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755081/ipad-small_flash.jpg XML http://www.pharmexec.com/pharmexec/Global/Pharma-2012-Hard-Times-Before-the-Harvest/ArticleStandard/Article/detail/755087?contextCategoryId=43776&ref=25 The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755087/Harvest-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Deals/Pharm-Execs-2012-Pipeline-Report/ArticleStandard/Article/detail/752361?contextCategoryId=43776&ref=25 It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752361/pipeline-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Leadership+Column/RaQualias-New-Spin-on-the-Startup/ArticleStandard/Article/detail/752341?contextCategoryId=43776&ref=25 Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752341/Nagahisa_interior2_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752341null XML http://www.pharmexec.com/pharmexec/Strategy/The-Payoff-for-Payers/ArticleStandard/Article/detail/752333?contextCategoryId=43776&ref=25 Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752333null XML http://www.pharmexec.com/pharmexec/Leadership+Column/The-Medicines-Adherence-Challenge/ArticleStandard/Article/detail/752368?contextCategoryId=43776&ref=25 Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma — but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda. 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752368/round-table-thumb21466761_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752368null XML http://www.pharmexec.com/pharmexec/Global+Report/Does-a-German-Launch-Make-Sense/ArticleStandard/Article/detail/747588?contextCategoryId=43776&ref=25 Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market? 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747588/Germany-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747588null XML http://www.pharmexec.com/pharmexec/Global+Report/Emerging-MarketsThe-Myths-and-Traps/ArticleStandard/Article/detail/744345?contextCategoryId=43776&ref=25 Success in the emerging markets depends significantly on navigating the myths and mental traps. 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744345/mousetrap-web-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Current+Issue/Inside-the-Mind-of-the-CEO/ArticleStandard/Article/detail/744338?contextCategoryId=43776&ref=25 Pharm Exec sits down with Steve Collis, CEO of AmerisourceBergen to discuss his agenda for retooling the drug distribution giant. 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744338/mind-of-CEO_thumb_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744338null XML http://www.pharmexec.com/pharmexec/Strategy/The-Permanent-Campaign/ArticleStandard/Article/detail/744323?contextCategoryId=43776&ref=25 The product launch has been transformed from a concentrated, all-out military assault to the subtle, persuasive art of electioneering. 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744323/Bernard_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744323null XML http://www.pharmexec.com/pharmexec/Global+Report/The-Power-of-Product-Development-Partnership/ArticleStandard/Article/detail/739264?contextCategoryId=43776&ref=25 Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739264/PDP-thumb_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Technology/Pharma-and-Social-Media-Ready-to-Make-Nice/ArticleStandard/Article/detail/739276?contextCategoryId=43776&ref=25 The time is right for industry to overcome its social media phobia once and for all. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739276/social-media_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739276null XML http://www.pharmexec.com/pharmexec/Global+Report/Front-and-Center-in-the-Fight-against-TB/ArticleStandard/Article/detail/739260?contextCategoryId=43776&ref=25 Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities. 2011-09-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Company+Profiles/Complex-Biologics-The-View-from-Teva/ArticleStandard/Article/detail/739258?contextCategoryId=43776&ref=25 Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739258null XML http://www.pharmexec.com/pharmexec/Global+Report/Should-the-US-Gamble-with-Risk-Sharing/ArticleStandard/Article/detail/739261?contextCategoryId=43776&ref=25 Especially when payers come to the table holding the best cards — leaving industry second-guessing its strategy. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739261/casino-chips.crop_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Innovation-at-Pfizer/ArticleStandard/Article/detail/734680?contextCategoryId=43776&ref=25 A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation. 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734680/Peck-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Partnerships/The-Adherence-Fight-A-TKO/ArticleStandard/Article/detail/734674?contextCategoryId=43776&ref=25 Why does the match against medicines compliance always seem to end in an easy knockout? 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734674null XML http://www.pharmexec.com/pharmexec/Strategy/Employers-Fighting-Non-Adherence/ArticleStandard/Article/detail/734668?contextCategoryId=43776&ref=25 A Q&A with Andrew Webber, President and CEO of the National Business Coalition on Health 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734668/webber_headshot_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734668null XML http://www.pharmexec.com/pharmexec/Noteworthy/Congressional-Investigations-What-Every-Exec-Shoul/ArticleStandard/Article/detail/734678?contextCategoryId=43776&ref=25 When faced with legislative scrutiny, be prepared, be truthful, and don't be afraid to say 'I don't know'... 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734678/grand_jury_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734678null XML http://www.pharmexec.com/pharmexec/Strategy/The-Slow-Dance-Toward-Obsolescence/ArticleStandard/Article/detail/734670?contextCategoryId=43776&ref=25 Does Big Pharma have the emotional connection and intellectual commitment to move with the pace of change? 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734670null XML http://www.pharmexec.com/pharmexec/Strategy/Is-the-Emerging-Market-a-Dated-Concept/ArticleStandard/Article/detail/734677?contextCategoryId=43776&ref=25 When it comes to the emerging markets, executing a few key elements of success are more important than ever. 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734677/World-map-lightbulb_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734677null XML http://www.pharmexec.com/pharmexec/Back+Page/Mind-the-Gap/ArticleStandard/Article/detail/734672?contextCategoryId=43776&ref=25 No one doubts the importance of health expenditures ? but then, euros, like dollars, don't grow on trees 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734672null XML http://www.pharmexec.com/pharmexec/Commentary/Giving-Press-Releases-New-Legs/ArticleStandard/Article/detail/734679?contextCategoryId=43776&ref=25 Social media now gives companies a plethora of creative ways to digitally spread recent company news and keep customers informed 2011-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322011/734679null XML http://www.pharmexec.com/pharmexec/Strategy/Planning-Beyond-the-Petri-Dish/ArticleStandard/Article/detail/730206?contextCategoryId=43776&ref=25 Pfizer's crizotinib development program combined organization, art, and science—and a large dose of unforeseen risk 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730206null XML http://www.pharmexec.com/pharmexec/Strategy/Cancer-From-Rut-to-Racetrack/ArticleStandard/Article/detail/730205?contextCategoryId=43776&ref=25 The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver? 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730205/driver_main.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730205/driver_flash.jpg XML http://www.pharmexec.com/pharmexec/Noteworthy/How-to-Be-More-Truthful/ArticleStandard/Article/detail/726096?contextCategoryId=43776&ref=25 Suggestions for testing new ways of addressing difficult issues of risk 2011-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242011/726096null XML http://www.pharmexec.com/pharmexec/Strategy/To-Genzyme-Quality-Data-Depends-on-Quality-Governa/ArticleStandard/Article/detail/726088?contextCategoryId=43776&ref=25 The payoff is superior performance in key areas such as clinical trials 2011-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242011/726088null XML http://www.pharmexec.com/pharmexec/Strategy/Managing-Product-Lifecycle/ArticleStandard/Article/detail/726106?contextCategoryId=43776&ref=25 Patent expiries are inevitable, but brand teams should look to graduate the sales curve 2011-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242011/726106null XML http://www.pharmexec.com/pharmexec/Sales/Honing-Reforms-from-Clinical-Development/ArticleStandard/Article/detail/707517?contextCategoryId=43776&ref=25 Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities 2011-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707517null XML http://www.pharmexec.com/pharmexec/Strategy/Ensuring-Drug-Quality-A-Complex-Task-in-a-Globaliz/ArticleStandard/Article/detail/703042?contextCategoryId=43776&ref=25 US Pharmacopeia has launched an ambitious moderniation campaign to ensure its standards keep pace with changes in the blobal marketplace 2011-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032011/703042/Approved_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032011/703042null XML http://www.pharmexec.com/pharmexec/Strategy/The-Steep-Slow-Climb/ArticleStandard/Article/detail/703041?contextCategoryId=43776&ref=25 A surve of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade 2011-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032011/703041/The-Steep,-Slow-Climb_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032011/703041null XML http://www.pharmexec.com/pharmexec/Strategy/Adherence-Equation-The-Code-is-Cracked/ArticleStandard/Article/detail/700436?contextCategoryId=43776&ref=25 Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine 2010-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512010/700436null XML http://www.pharmexec.com/pharmexec/Strategy/Specialty-Care-Medicines-Managing-the-Impact-of-US/ArticleStandard/Article/detail/695704?contextCategoryId=43776&ref=25 There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market? 2010-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472010/695704null XML http://www.pharmexec.com/pharmexec/Marketing/Health-20-A-Game-changer-in-the-Health-Care-Indust/ArticleStandard/Article/detail/689988?contextCategoryId=43776&ref=25 With the growth of online technology and mobile innovations, health information has never been more accessible. Given the constraints of working in a tightly regulated environment, life sciences companies have moved slowly to adopt Health 2.0, treating it as a minor component of their commercial strategies and marketing plans. 2010-10-05T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412010/689988null REMOTE http://www.pharmexec.com/pharmexec/Technology/Roche-Sets-a-New-Social-Media-Standard/ArticleStandard/Article/detail/690975?contextCategoryId=43776&ref=25 Will Roche's precedent push the regulatory community to create standards that will level the playing field for all contenders? 2010-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690975/95892466_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690975null XML http://www.pharmexec.com/pharmexec/Strategy/When-the-Payer-IS-the-Player/ArticleStandard/Article/detail/690978?contextCategoryId=43776&ref=25 As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? 2010-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690978/Untitle1_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690978null XML http://www.pharmexec.com/pharmexec/Strategy/Knowledge-Based-Outsourcing-Driving-Deeper-Insight/ArticleStandard/Article/detail/690980?contextCategoryId=43776&ref=25 Tracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why. 2010-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690980/Untitled-5_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690980null XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Optimizing-TV-Advertising-Placements-amp-Results/ArticleStandard/Article/detail/690972?contextCategoryId=43776&ref=25 Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives 2010-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690972null XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Tracking-Meetings-in-Troubled-Times/ArticleStandard/Article/detail/687366?contextCategoryId=43776&ref=25 Scrutiny of pharmaceutical promotion and gifts to practitioners has intensified, with more states enacting reporting requirements. In May, the federal government passed the Physician Payment Sunshine Act. What kind of impact is all this having on meetings and physician attendance? 2010-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687366null XML http://www.pharmexec.com/pharmexec/Strategy/Looking-Beyond-the-Patent-Cliff/ArticleStandard/Article/detail/687368?contextCategoryId=43776&ref=25 Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP 2010-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687368/headshot_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687368null XML http://www.pharmexec.com/pharmexec/Strategy/Is-There-a-Balm-for-Gilead/ArticleStandard/Article/detail/687362?contextCategoryId=43776&ref=25 A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days? 2010-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687362/49_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687362null XML http://www.pharmexec.com/pharmexec/Strategy/Finding-the-Hidden-Behavior-Solutions/ArticleStandard/Article/detail/687360?contextCategoryId=43776&ref=25 When neither attitudes nor personality drive behavior, Pharma must look to social norms to understand consumer adherence issues 2010-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687360null XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Where-Prescribing-Oncologists-Go-for-Their-Informa/ArticleStandard/Article/detail/687356?contextCategoryId=43776&ref=25 Marketers need to understand how informal influencers are beginning to replace traditional channels as the favored way for doctors to receive product information from drug manufacturers, and, in turn, how best to leverage peer influence in designing effective meetings and events 2010-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382010/687356null XML http://www.pharmexec.com/pharmexec/Strategy/Mr-Quality-Goes-to-Washington/ArticleStandard/Article/detail/682856?contextCategoryId=43776&ref=25 Berwick's mission: To successfully translate the new healthcare bill into practice. 2010-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682856/image_1_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682856null XML http://www.pharmexec.com/pharmexec/Strategy/Strategies-for-Emerging-Markets-Seven-Keys-to-the-/ArticleStandard/Article/detail/682854?contextCategoryId=43776&ref=25 It's back to the future in Pharm Exec's second-annual review of industry prospects in the IMS "Pharmerging 17" 2010-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682854/image_4_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682854null XML http://www.pharmexec.com/pharmexec/Strategy/Competition-The-Heat-is-On/ArticleStandard/Article/detail/682855?contextCategoryId=43776&ref=25 Not only is the rivalry getting intense, pharma firms are not doing enough to create the organizational mandate that puts competition front and center in strategy 2010-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682855/image_2_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682855null XML http://www.pharmexec.com/pharmexec/Strategy/China-Behind-the-Screen/ArticleStandard/Article/detail/681188?contextCategoryId=43776&ref=25 To shed some light on China's potential, Pharm Exec sat down with Peter Young, President and Managing Partner of Young & Partners, who recently met with government and industry officials to review the investment and M&A climate for medicines. 2010-07-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312010/681188null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Rethinks-Rep-Compensation/ArticleStandard/Article/detail/680852?contextCategoryId=43776&ref=25 Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented. 2010-07-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312010/680852null HTML http://www.pharmexec.com/pharmexec/Strategy/PhRMA-Announces-Billy-Tauzins-Successor/ArticleStandard/Article/detail/678934?contextCategoryId=43776&ref=25 John Castellani received the nod from PhRMA on Tuesday to take over the role of president and CEO in September. 2010-07-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292010/678934null HTML http://www.pharmexec.com/pharmexec/Strategy/Response-to-the-Fiscal-Crisis-The-Valuing-Conversa/ArticleStandard/Article/detail/678273?contextCategoryId=43776&ref=25 As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough? 2010-07-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282010/678273null HTML http://www.pharmexec.com/pharmexec/Marketing/Managing-the-Middle/ArticleStandard/Article/detail/678714?contextCategoryId=43776&ref=25 Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line. 2010-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292010/678714/Thumbnail_evolve_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292010/678714null XML http://www.pharmexec.com/pharmexec/News+Analysis/Mixed-Criticism-on-Avandia-Effectiveness/ArticleStandard/Article/detail/676969?contextCategoryId=43776&ref=25 GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks. 2010-06-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/272010/676969null HTML http://www.pharmexec.com/pharmexec/Strategy/Emerging-Pharma-Leaders-2010/ArticleStandard/Article/detail/676060?contextCategoryId=43776&ref=25 Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters—and how they plan to lead the industry through the turbulent times ahead. 2010-06-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262010/676060/i1_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262010/676060null XML http://www.pharmexec.com/pharmexec/News+Analysis/Pfizer-Pulls-Leukemia-Treatment/ArticleStandard/Article/detail/675777?contextCategoryId=43776&ref=25 Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs? 2010-06-23T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262010/675777null HTML http://www.pharmexec.com/pharmexec/Strategy/Riding-the-Wave/ArticleStandard/Article/detail/674795?contextCategoryId=43776&ref=25 A new "upstream" healthcare model may help deliver on the longstanding promise of personalized medicine. 2010-06-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/252010/674795/PE0610_person_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/252010/674795null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Merck-Reveals-New-Trial-Network-for-Oncology/ArticleStandard/Article/detail/673535?contextCategoryId=43776&ref=25 Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline. 2010-06-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242010/673535null HTML http://www.pharmexec.com/pharmexec/Strategy/Crackdown-on-the-C-Suite/ArticleStandard/Article/detail/676059?contextCategoryId=43776&ref=25 Lewis Morris, top lawyer in HHS's office of inspector general, explains his new move to target pharma execs for serious and ongoing healthcare fraud. 2010-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262010/676059null XML http://www.pharmexec.com/pharmexec/Profiles/QampA-Geno-Germano/ArticleStandard/Article/detail/665668?contextCategoryId=43776&ref=25 Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry. 2010-05-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665668/Geno_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665668null XML http://www.pharmexec.com/pharmexec/Whitepaper/The-US-Health-Care-Reform-Opportunity-Implications/ArticleStandard/Article/detail/669465?contextCategoryId=43776&ref=25 This report provides a summary of the health care reform issues that have emerged as important to related industries. For life sciences companies in particular, the implications of those issues are examined and a new approach in addressing the government as a key stakeholder is explored. 2010-05-10T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202010/669465null REMOTE http://www.pharmexec.com/pharmexec/Strategy/Pharmas-Orphans/ArticleStandard/Article/detail/670568?contextCategoryId=43776&ref=25 The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it? 2010-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212010/670568null XML http://www.pharmexec.com/pharmexec/Strategy/Code-Orange/ArticleStandard/Article/detail/670561?contextCategoryId=43776&ref=25 How will US healthcare reform affect drug pricing, revenue, and compliance? 2010-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212010/670561null XML http://www.pharmexec.com/pharmexec/News+Analysis/Biotech-Industry-Profits-Grow-37B/ArticleStandard/Article/detail/667300?contextCategoryId=43776&ref=25 After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth? 2010-04-28T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182010/667300null HTML http://www.pharmexec.com/pharmexec/Profiles/Woman-of-the-Year-Deirdre-Connelly/ArticleStandard/Article/detail/665663?contextCategoryId=43776&ref=25 As head of GSK's North American pharma, Deirdre Connelly has the daunting challenge of trying to turn around the sluggish US market. If she succeeds, Connelly may find herself auditioning as the first female Big Pharma CEO. 2010-04-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665663/women_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665663null XML http://www.pharmexec.com/pharmexec/Strategy/Sanofi-Aventis-Cuts-400-Jobs/ArticleStandard/Article/detail/664380?contextCategoryId=43776&ref=25 Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales. 2010-04-07T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152010/664380null HTML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-and-Pfizer-to-Discount-Pneumonia-Vaccines-for-/ArticleStandard/Article/detail/662490?contextCategoryId=43776&ref=25 Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts. 2010-03-24T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132010/662490null HTML http://www.pharmexec.com/pharmexec/Strategy/Emerging-Markets-to-Account-for-Half-of-Market-Gro/ArticleStandard/Article/detail/661718?contextCategoryId=43776&ref=25 A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity? 2010-03-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122010/661718null HTML